|
Global Vaccine Market Forecast to 2012
By Shushmul Maheshwari
RNCOS E-Services Pvt. Ltd.
Email: press@rncos.com
http://www.rncos.com/
Thursday - October 29, 2009
Category: Investment, Biotech
Vaccines have emerged as one of the most lucrative segment in the global pharmaceutical industry. With a projected CAGR of over 13% during 2009-2012, the industry will emerge as the fastest growing therapy area. The US and Europe represent the two largest vaccine markets in the world and will continue experiencing healthy growth rate in future.
As per our research "Global Vaccine Market Forecast to 2012", the segment of pediatric vaccines presently dominates the global vaccine market; however, adult vaccine segments will define the future growth directions. The cancer vaccine market, led by cervical cancer vaccines, is presently one of the most lucrative areas for vaccine manufacturers.
Owing to lower margins and the mature nature of these markets, the basic and enhanced pediatric markets are expected to show insignificant growth in future. On the other hand, launch of a number of new vaccines will make the addiction, cancer and proprietary pediatrics/adolescent vaccine market highly dynamic. On a whole, the global vaccine market is expected to register revenues in excess of US$ 34 Billion by 2012.
Our analysis of the competitive landscape of the global vaccine market shows a highly concentrated structure, with the top four players accounting for around 74% of the total market in 2008.
Our report gives an extensive and objective analysis on the global vaccine market. It investigates both the past and current trends in the vaccine market, and outlines the future trends shaping the industry. It comprehensively assesses the performance of vaccines, both in the market as well as in the developing stage. Based on various present and future indicators, the report evaluates the prospects of various vaccine se gments.
The report can, thus, prove critical to manufacturers/investors preparing to enter the vaccine market.
The report includes forecast till 2012 on:
- Global Vaccine Revenues
- Basic Pediatrics Vaccine Revenues
- Enhanced Pediatrics Vaccine Revenues
- Proprietary Pediatrics/Adolescent Vaccine Revenues
- Adult Vaccine Revenues
- Influenza Vaccine Revenues
- Cancer Vaccines Revenues
- Share of Key Players in Vaccine Market
- Revenues of Key Vaccine Brands
A section on the market landscape has also been included in the report to give a category-wise overview of the key players, including Sanofi-Aventis, GlaxoSmithKline, Merk & Co., Inc, Novartis and Wyeth, operating in the global vaccine market.
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM153.htm
Check DISCOUNTED REPORTS on: http://www.rncos.com
About RNCOS:
RNCOS, incorporated in the year 2002, is an industry research firm. We are a team of industry experts who analyze data collected from credible sources. We provide industry insights and analysis that helps corporations to take timely and accurate business decision in today's globally competitive environment.
Published at the www.InvestorIdeas.com Investing, Research and Industry Articles News Feed - Investorideas.com Financial Article Feed
Become an Investorideas.com Member and access some of our best investor research tools: Investing in Renewable Energy, Environment and Water Stocks
Become an Investorideas.com Member - Gain login access to 8 global stock directories including renewable energy stocks directory, environment stocks, water stocks, fuel cell stocks, biotech stocks, defense stocks, natural gas stocks, oil and gas stocks as well as the Insiders Corner investor newsletter covering insider buying trends on small cap stocks.
Investors: Sign up for free newsletter, stock and sector news alerts at Investorideas.com. Or publish your own stock picks and share your investing and trading ideas with other investors. Publish your investor ideas today!
www.InvestorIdeas.com - Big Ideas for the Small Cap Investor
Disclaimer: The views and opinions expressed in the research published are those of the individual companies and writers and not necessarily those of Investorideas.comŽ, or any of the industry sector portals . At the time of publication, writers may hold positions in the stocks or companies mentioned.
Investorideas.comŽ or any of the industry sector portals cannot assure accuracy of the research presented. Investors are encouraged to research and verify facts and under no circumstances is Investorideas.comŽ endorsing the content as a recommendation to buy or sell stock.
|
